Interim results from the first nine participants in a Phase 2 clinical trial testing Arcturus Therapeutics’ experimental inhaled therapy…
Lila Levinson, PhD
Lila is a Science Writer at BioNews. She completed her PhD in neuroscience at the University of Washington, where she studied how the natural flexibility of the human brain can be used to promote recovery after injury. Previously, she has written about science for The Dallas Morning News and the University of Washington Computational Neuroscience Center. She enjoys exploring the Pacific Northwest and spending time with her cat, Fibonacci.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Lila Levinson, PhD
A new noninvasive prenatal test for cystic fibrosis (CF) and three other inherited conditions, launched by Natera, uses…
The first participant has been dosed in a Phase 2b clinical trial testing BiomX’s experimental inhaled therapy BX004 in adults…
Alyftrek has been approved by the European Commission to treat cystic fibrosis (CF) patients 6 years and older who…
Although infants with cystic fibrosis (CF) may have lung function abnormalities between the ages of 3 months and 2…
SION-719 and SION-451, two NBD1 stabilizers Sionna Therapeutics is developing to restore CFTR protein function in cystic fibrosis (CF),…